Premium
Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. class III β‐tubulin
Author(s) -
Katsetos Christos D.,
Dráberová Eduarda,
Legido Agustin,
Dumontet Charles,
Dráber Pavel
Publication year - 2009
Publication title -
journal of cellular physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.529
H-Index - 174
eISSN - 1097-4652
pISSN - 0021-9541
DOI - 10.1002/jcp.21870
Subject(s) - tubulin , isotype , carcinogenesis , glioma , cancer research , biology , microtubule , targeted therapy , glioblastoma , malignant transformation , cancer , brain tumor , tumor progression , immunology , medicine , antibody , genetics , pathology , monoclonal antibody
Glioblastoma multiforme (GBM) is the most common and deadliest form of primary brain cancer in adults. Despite advances in molecular biology and genetics of gliomas currently there is no effective treatment or promising molecularly targeted experimental therapeutic strategies for these tumors. In previous studies we have shown aberrant overexpression of the class III β‐tubulin isotype (βIII‐tubulin) in GBM and have proposed that this change may reflect perturbations in microtubule dynamics associated with glioma tumorigenesis, tumor progression and malignant transformation into GBM. This minireview focuses on microtubules and tubulin as emerging targets in potential therapy of GBM using a new class of βIII‐tubulin‐targeted drugs in the light of recent developments concerning the function and potential role of this isotype in clinically aggressive tumor behavior, cancer stem cells, tumor hypoxia and chemoresistance to tubulin binding agents, principally taxanes. J. Cell. Physiol. 221: 505–513, 2009. © 2009 Wiley‐Liss, Inc.